<DOC>
	<DOC>NCT01339299</DOC>
	<brief_summary>The study is a prospective, randomised, controlled, and non-blinded multi-center pilot study to evaluate endocrine efficacy of recombinant luteinizing hormone versus recombinant human chorionic gonadotropin administered during controlled ovarian stimulation for IVF/ICSI in normogonadotrophic women.</brief_summary>
	<brief_title>Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART)</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<criteria>Women who plan to undergo IVF or ICSI treatment Woman's age &gt; 18 years but â‰¤ 35 years Regular menstrual cycle (2534 days) BMI 18 to 30 inclusive Signed patient information and informed consent forms PCOS More than 2 prior IVF/ICSI attempts Diabetes mellitus, epilepsy, lever, kidney, heart and metabolism disorders, according to the Investigator's assessment.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>COS</keyword>
	<keyword>ART</keyword>
	<keyword>Infertility</keyword>
</DOC>